Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
22
pubmed:dateCreated
2005-10-27
pubmed:abstractText
A series of oxamyl dipeptides were optimized for pan caspase inhibition, anti-apoptotic cellular activity and in vivo efficacy. This structure-activity relationship study focused on the P4 oxamides and warhead moieties. Primarily on the basis of in vitro data, inhibitors were selected for study in a murine model of alpha-Fas-induced liver injury. IDN-6556 (1) was further profiled in additional in vivo models and pharmacokinetic studies. This first-in-class caspase inhibitor is now the subject of two Phase II clinical trials, evaluating its safety and efficacy for use in liver disease.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0022-2623
pubmed:author
pubmed-author:AjaTeresaT, pubmed-author:ArmstrongRobert ARA, pubmed-author:BaiXuX, pubmed-author:ChenLong-ShiuhLS, pubmed-author:ChenNingN, pubmed-author:ChingBrettB, pubmed-author:ContrerasPatriciaP, pubmed-author:DiazJose-LuisJL, pubmed-author:FisherCraig DCD, pubmed-author:FritzLawrence CLC, pubmed-author:GladstonePatriciaP, pubmed-author:GroesslToddT, pubmed-author:GuXinX, pubmed-author:HerrmannJuliaJ, pubmed-author:HirakawaBrad PBP, pubmed-author:HoglenNiel CNC, pubmed-author:JahangiriKathy GKG, pubmed-author:KalishVincent JVJ, pubmed-author:KaranewskyDonald SDS, pubmed-author:KodandapaniLalithaL, pubmed-author:KrebsJosephJ, pubmed-author:LintonSteven DSD, pubmed-author:McQuistonJeffJ, pubmed-author:MedunaSteven PSP, pubmed-author:NalleyKipK, pubmed-author:RobinsonEdward DED, pubmed-author:SayersRobert ORO, pubmed-author:SebringKristenK, pubmed-author:SpadaAlfred PAP, pubmed-author:TernanskyRobert JRJ, pubmed-author:TomaselliKevin JKJ, pubmed-author:UllmanBrett RBR, pubmed-author:ValentinoKaren LKL, pubmed-author:WeeksSuzanneS, pubmed-author:WinnDavidD, pubmed-author:WuJoe CJC, pubmed-author:YeoPaulineP, pubmed-author:ZhangCheng-zhiCZ
pubmed:issnType
Print
pubmed:day
3
pubmed:volume
48
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
6779-82
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:16250635-Adult, pubmed-meshheading:16250635-Alanine Transaminase, pubmed-meshheading:16250635-Animals, pubmed-meshheading:16250635-Apoptosis, pubmed-meshheading:16250635-Aspartate Aminotransferases, pubmed-meshheading:16250635-Biological Availability, pubmed-meshheading:16250635-Caspase 3, pubmed-meshheading:16250635-Caspases, pubmed-meshheading:16250635-Cholestasis, pubmed-meshheading:16250635-Clinical Trials, Phase I as Topic, pubmed-meshheading:16250635-Half-Life, pubmed-meshheading:16250635-Hepatitis C, Chronic, pubmed-meshheading:16250635-Hepatocytes, pubmed-meshheading:16250635-Humans, pubmed-meshheading:16250635-Jurkat Cells, pubmed-meshheading:16250635-Liver, pubmed-meshheading:16250635-Liver Diseases, pubmed-meshheading:16250635-Mice, pubmed-meshheading:16250635-Pentanoic Acids, pubmed-meshheading:16250635-Rats, pubmed-meshheading:16250635-Structure-Activity Relationship
pubmed:year
2005
pubmed:articleTitle
First-in-class pan caspase inhibitor developed for the treatment of liver disease.
pubmed:affiliation
Idun Pharmaceuticals, 9380 Judicial Drive, San Diego, CA 92121, USA. slinton@idun.com
pubmed:publicationType
Journal Article